Shilpa Chitnis, M.D., Ph.D.
Professor

Shilpa Chitnis is Associate Professor of Neurology and Neurotherapeutics at UT Southwestern Medical Center in Dallas, Texas.  She has been involved in the care of patients with movement disorders for the past 12 years.

Shilpa received her medical degree from Grant Medical College in Bombay, India.  She completed her PhD in Pharmacology from Tulane University, New Orleans, LA along with her Neurology residency also from Tulane.  She completed a fellowship in movement disorders from Louisiana State University Medical Center in New Orleans, LA.

 She serves as fellowship director for movement disorders and associate program director for the Neurology residency at UT Southwestern. She is a member of the American Academy of Neurology and the Movement Disorders Society. She recently authored and co-edited a handbook of movement disorders published by the Oxford American Neurological Library. She is a author of multiple peer reviewed journal publications and editor for numerous scientific journals including Movement Disorders journal, Jama Neurology.

Dr. Chitnis is intricately involved in medical student, resident and fellow education in Neurology and movement disorders.  She organizes didactic lecture series for the residency program along with another Neurology faculty colleague and is co-director for Grand Rounds organization for the Neurology department. Her philosophy towards patient care entails a comprehensive approach including family members and all ancillary personnel involved in the care of patients including physical and speech therapists, primary care doctors and other specialists. She believes that your health is your responsibility and believes in making patients accountable for their health and care.  She focuses on comprehensive counseling to help patients understanding their disease profile, medications and specific things they need to do to manage their disease optimally. 

 Dr. Chitnis has been married for 15 years and has a 10 year old daughter who is the apple of her eye. She enjoys reading, music, movies, working out, traveling and creative cooking. 

 

Internship/Residency

Tulane University School of Medicine (2002), Neurology

Fellowship

LSU Health Sciences Center (2003), Movement Disorders

• 1. Co-PI: ?NET-PD LS-1 Creatine in Parkinson?s disease?. National Institute of Neurological Disorders and Stroke (NINDS), 2008-present 2. Co-PI: FS-Zone ?A Multi-Center, Double-Blind, Placebo-Controlled Phase II Study of Pioglitazone in Early Parkinson?s Disease?, 2012-present 3. Co-PI: ?Diagnostic and prognostic biomarkers for Parkinson's disease.? 9/30/2012-present, Study Sponsor: NINDS, grant number 1U01NS082148, $2,281,869 4. Co-PI: ?A Phase 3, 12-week, Double-Blind, Placebo-Controlled, Ran
• Dementia in Parkinson's Disease
• New and Emerging Therapies for Parkinson's Disease

Featured Publications

History, applications, and mechanisms of deep brain stimulation.

Miocinovic S, Somayajula S, Chitnis S, Vitek JL JAMA Neurol 2013 Feb 70 2 163-71

Gene-expression signatures: biomarkers toward diagnosing multiple sclerosis.

Tossberg JT, Crooke PS, Henderson MA, Sriram S, Mrelashvili D, Chitnis S, Polman C, Vosslamber S, Verweij CL, Olsen NJ, Aune TM Genes Immun. 2012 Feb 13 2 146-54

Outcomes from switching from rotigotine patch to alternate therapies in Parkinson's disease.

Chitnis S, Jaffery M, Dewey RB Int. J. Neurosci. 2012 Jan 122 1 22-5

Deep brain stimulation artifact in needle electromyography.

Sadeghian H, Chitnis S, Elliott JL Arch. Neurol. 2010 Aug 67 8 1030

Monoamine Oxidase Type B Inhibitors in the Treatment of Early Parkinson Disease?.

Cherian Abraham Karunapuzha, Shilpa Chitnis and Richard B. Dewey Jr. US Neurology 2010 1 6 36-40

Rivastigmine in Parkinson's disease dementia.

Chitnis S, Rao J Expert Opin Drug Metab Toxicol 2009 Aug 5 8 941-55

?Tetrabenazine in Huntington?s Disease Chorea?.

Shilpa Chitnis and Cherian Abraham Karunapuzha. Clinical Medicine:Therapeutics 2009:1 669-681 2009 1 669-681

Optimizing therapeutic effects in patients with comorbidities: drug-resistant tremor, autonomic dysfunction, psychiatric disorders, and cognitive impairment.

Chitnis S Neurol Clin 2008 Aug 26 3 Suppl S29-44, v-vi

Ropinirole treatment for restless legs syndrome.

Chitnis S Expert Opin Drug Metab Toxicol 2008 May 4 5 655-64

Zidovudine (AZT) treatment suppresses granulocyte-monocyte colony stimulating factor receptor type alpha (GM-CSFR alpha) gene expression in murine bone marrow cells.

Chitnis S, Mondal D, Agrawal KC Life Sci. 2002 Jul 71 8 967-78

 Featured Books

Movement Disorders

Shilpa Chitnis, MD, PhD/Richard B. Dewey Jr. M.D. (Ed.) (2010). New York, Oxford University Press (OUP)

• Robert J. Heath Society, Tulane University, New Orleans, Louisiana
  Resident Award for Excellence in Scientific Writing (2002)

• American Academy of Neurology
• Movement Disorders Society